NIH gives $8M to University of Pittsburgh School of Medicine for myositi...( PITTSBURGH Aug. 13 Researchers from ...)

NIH gives $8M to University of Pittsburgh School of Medicine for myositis research

PITTSBURGH, Aug. 13 Researchers from the division of rheumatology and clinical immunology at the University of Pittsburgh School of Medicine are leading a worldwide effort to study a treatment for a rare autoimmune disorder called myositis, thanks to a five-year, $8 million contract from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health (NIH).

Chester V. Oddis, M.D., professor of medicine at the University of Pittsburgh School of Medicine, is principal investigator for the effort, which involves 36 other scientists from 18 states and five countries, including Canada, the Czech Republic, Sweden, England and the United States.

Myositis is a general term for several conditions, including dermatomyositis, polymyositis, inclusion-body myositis and juvenile forms of myositis. Also known as inflammatory myopathies, they are musculoskeletal disorders characterized by muscle weakness thought to be autoimmune diseases. This means that the bodys immune system, which normally fights infections and viruses, for reasons unknown turns on itself and attacks the muscle tissue and sometimes skin, joints and lungs, causing rash, arthritis and shortness of breath.

The University of Pittsburgh-led study will evaluate the effectiveness of a drug called rituximab in adults and children diagnosed with dermatomyositis (a disease that causes muscle weakness and rash) and adults diagnosed with polymyositis, which is not associated with a rash. The study doctors want to know whether rituximab improves symptoms of these diseases.

Rituximab is a monoclonal antibody used and approved since 1997 by the Food and Drug Administration (FDA) for the treatment of B-cell non-Hodgkins lymphoma. It was approved in February 2006 for adult rheumatoid arthritis patients with an inadequate response to anti-TNF (tumor necrosis factor) agents. In this study, rituximab is considered to be experimental
'"/>

Contact: Michele Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
13-Aug-2007

Page: 1 2
Related biology news :

1. Brain blood flow gives clues to treating depression
2. Immune system escape hatch gives cancer cells traction
3. Investigating Life in Extreme Environments report gives hints on facts of life
4. 5.9 million award gives UK aging research a new lease on life
5. Neuronal activity gives clues to working memory
6. Study of damaged gene gives insight into causes of mental illness
7. Human pubic lice acquired from gorillas gives evolutionary clues
8. DNA gives new perspectives to understand the mysteries of nature
9. NIH gives PITT $13 million grant for chronic obstructive pulmonary disease research
10. Study gives clues about how deadly bacterium gains foothold
11. Resilient form of plant carbon gives new meaning to term older than dirt

Post Your Comments: